Radiotherapy Combined with Pyrotinib Plus Capecitabine in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases: A Single-Arm, Exploratory Trial

被引：0
|
作者：
Wang, J. [1 ]
Wang, P. [2 ]
You, J. [2 ]
Wang, X. [3 ]
Hou, H. [2 ]
Zhang, B. [2 ]
Chai, Y. [2 ]
Cao, Y. [2 ]
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2625
引用
收藏
页码：E283 / E284
页数：2
相关论文
共 50 条
  • [1] Radiotherapy combined with pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases: A single-arm, exploratory trial
    Wang, Jing
    Wang, Ping
    You, Jinqiang
    Hou, Hailing
    Zhang, Baozhong
    Chai, Yanlan
    Cao, Yuanjie
    Zhang, Bin
    Wang, Xu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
    Yan, Min
    Ouyang, Quchang
    Sun, Tao
    Niu, Limin
    Yang, Jin
    Li, Li
    Song, Yuhua
    Hao, Chunfang
    Chen, Zhanhong
    Orlandi, Armando
    Ishii, Naohiro
    Takabe, Kazuaki
    Franceschini, Gianluca
    Ricci, Francesco
    Verschraegen, Claire
    Liu, Zhenzhen
    Zhang, Mengwei
    Lv, Huimin
    Liu, Liping
    Yang, Xiaohong
    Xiao, Huawu
    Gao, Zhichao
    Li, Xiaorui
    Dong, Fangyuan
    Chen, Xiuchun
    Qiao, Jianghua
    Zhang, Guifang
    LANCET ONCOLOGY, 2022, 23 (03): : 353 - 361
  • [3] Pyrotinib in combination with letrozole for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: A multicenter, single-arm, phase II trial
    Ouyang, Quchang
    Xiong, Huihua
    Yan, Min
    Zhong, Jincai
    Ran, Li
    Luo, Ting
    Liu, Liping
    Li, Jing
    Yang, Xiaohong
    Xiao, Huawu
    Xie, Ning
    Wu, Hui
    Gao, Jianxiang
    Lu, Jun
    Hu, Xuming
    Hu, Zheyu
    Tian, Can
    Shui, Zhengrong
    Cao, Min
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
    Xie, Xiao-Feng
    Zhang, Qiu-Yi
    Huang, Jia-Yi
    Chen, Li-Ping
    Lan, Xiao-Feng
    Bai, Xue
    Song, Lin
    Xiong, Shui-Ling
    Guo, Si-Jia
    Du, Cai-Wen
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (01) : 93 - 101
  • [5] Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
    Xiao-Feng Xie
    Qiu-Yi Zhang
    Jia-Yi Huang
    Li-Ping Chen
    Xiao-Feng Lan
    Xue Bai
    Lin Song
    Shui-Ling Xiong
    Si-Jia Guo
    Cai-Wen Du
    Breast Cancer Research and Treatment, 2023, 197 : 93 - 101
  • [6] Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial
    Jin, Nan
    Xu, Yi
    Wang, Siqi
    Sun, Chunxiao
    Yan, Xueqi
    Yang, Fan
    Liang, Yan
    Chen, Weiwei
    Huang, Xiang
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (01): : 31 - 37
  • [7] Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR plus ) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial
    Wang, Ying
    Zhao, Jianli
    Yuan, Zhongyu
    Zou, Guorong
    Li, Haiyan
    Ding, Linxiaoxiao
    Yang, Yaping
    Chai, Jie
    Liu, Donggeng
    Yao, Herui
    CANCER RESEARCH, 2022, 82 (04)
  • [8] Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
    Yan, Min
    Ouyang, Quchang
    Sun, Tao
    Niu, Limin
    Yang, Jin
    Li, Li
    Song, Yuhua
    Hao, Chunfang
    Chen, Zhanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
    Nancy U. Lin
    Rachel A. Freedman
    Naren Ramakrishna
    Jerry Younger
    Anna Maria Storniolo
    Jennifer R. Bellon
    Steven E. Come
    Rebecca S. Gelman
    Gordon J. Harris
    Mark A. Henderson
    Shannon M. MacDonald
    Anand Mahadevan
    Emily Eisenberg
    Jennifer A. Ligibel
    Erica L. Mayer
    Beverly Moy
    April F. Eichler
    Eric P. Winer
    Breast Cancer Research and Treatment, 2013, 142 : 405 - 414
  • [10] A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
    Lin, Nancy U.
    Freedman, Rachel A.
    Ramakrishna, Naren
    Younger, Jerry
    Storniolo, Anna Maria
    Bellon, Jennifer R.
    Come, Steven E.
    Gelman, Rebecca S.
    Harris, Gordon J.
    Henderson, Mark A.
    MacDonald, Shannon M.
    Mahadevan, Anand
    Eisenberg, Emily
    Ligibel, Jennifer A.
    Mayer, Erica L.
    Moy, Beverly
    Eichler, April F.
    Winer, Eric P.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 142 (02) : 405 - 414
12345